Гормональная Терапия С Использованием Агонистов И Антагонистов Лютеинизи- Рующего Гормона Релизинг Гормона У Больных Раком Предстательной Железы

Нюшко, К. М.; Krasheninnikov, A. A.; Головащенко, М. П.; Каприн, А. Д.

doi:10.17709/2409-2231-2014-1-69-73

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Нюшко период наблюдения за пациентами с местно-распространенным РПЖ после ЛРПЭ и РТЛАЭ составил 60 и 3-205 мес (медиана 60 мес) соответственно. Из графиков Каплана-Майера, представленных в этих работах и отражающих частоту и сроки формирования БХР, или безрецидивную выживаемость, видно, что возникновение БХР практически в равной степени возможно на любом этапе отдаленного послеоперационного периода -через несколько месяцев или через несколько лет после вмешательства [24,35]. Однако, как отмечают A. Briganti и соавт., формирование БХР в течение первых 36 мес после операции (ранний БХР) является неблагоприятным прогностическим фактором: среди пациентов с ранним БХР показатель онкоспецифической смертности статистически значимо превышал таковой у лиц с более поздним развитием БХР (19,1 и 4,4 % соответственно) [34].…”

Section: Discussionunclassified

Outcomes of radical prostatectomy in treatment of locally advanced prostate cancer: clinical observations

Popov¹,

Guseynov

Орлов³

et al. 2023

Onkourologiâ

View full text Add to dashboard Cite

Background. Radical prostatectomy in treatment of locally advanced prostate cancer is currently recommended as one of the stages of multimodal therapy. Despite this, the expediency of surgical intervention remains a subject of discussion: based on the results of their own research, supporters of surgical tactics for treatment of locally advanced prostate cancer point to the effectiveness and relative safety of radical prostatectomy, opponents point to the high probability of a positive surgical edge associated with the operation, local tumor recurrence, lymphogenic metastasis, and formation of distant metastases.Aim. To evaluate the outcomes of laparoscopic radical prostatectomy performed in combination with expanded pelvic lymphadenectomy in treatment of prostate adenocarcinoma T3a–3bN0M0.Materials and methods. The perioperative, functional, and oncological results of surgical treatment of patients with locally advanced prostate cancer (n = 32) aged between 46 years to 71 years were analyzed. The follow-up period averaged 9–36 months (median 13 months).Results. Mean total duration of surgical intervention and mean volume of intraoperative blood loss were 182.69 ± 3.99 minutes and 253.06 ± 9.80 ml, respectively. Overestimation of the clinical stage of the disease, according to histological examination of the surgical material, was observed in 6.3 % of patients. After the intervention, the function of urinary retention was preserved and did not require correction in 65.6 % of men. In all patients 6 months after the operation, the urinary volume, maximum and mean urine flow rates were normalized, and there was a trend toward a decrease in the post-void residual volume. During the entire follow-up period, there were no signs of biochemical relapse in 78.1 % of patients. None of the participants dropped out of the study due to death.Conclusion. Over the last 20 years in specialized medical periodicals, author teams from various countries have shown the immediate and remote (follow-up period from 3 to 20 years) outcomes of radical surgical treatment of locally advanced prostate cancer in at least 80,000 patients in total, while the criterion for exclusion from research was adjuvant therapy. The authors’ conclusions indicate the effectiveness and relative safety of surgical treatment of locally advanced prostate cancer, as well as the importance of extended pelvic lymphadenectomy, which allows to optimize the tactics of adjuvant therapy if necessary. The results of our own observations are completely comparable with the literature data. Currently, scientific research is continuing with the aim of improving the outcomes of surgical treatment of locally advanced prostate cancer, in particular clarifying the role of individual prognostic factors, improving prediction techniques and choosing a rational scheme of treatment measures.

show abstract

Section: Discussionunclassified

Outcomes of radical prostatectomy in treatment of locally advanced prostate cancer: clinical observations

Popov¹,

Guseynov

Орлов³

et al. 2023

Onkourologiâ

View full text Add to dashboard Cite

show abstract

“…Мони-торинг в этих условиях дает возможность не только про-анализировать характер и объем лечения, но и расширить круг сведений о его отдаленных результатах, спектре и частоте нежелательных явлений [20][21][22]. Оценка резуль-татов лечения препаратом лейпрорелина ацетат в кли-нической практике уже проводилась в ряде европейских стран.…”

Section: Discussionunclassified

Experience with a luteinizing hormone-releasing hormone agonist in patients with prostate cancer

Березин¹,

Milovanov²,

Иванников³

2016

Onkol. Z. im. P.A. Gercena

View full text Add to dashboard Cite

Ключевые слова: гормональная терапия, рак предстательной железы, агонист лютеинизирующего гормона -рилизинг-гормон, лейпрорелин ацетат, тестостерон, ПСА, андрогенная блокада.The efficiency of hormone therapy was analyzed in patients with locally advanced or metastatic prostate cancer. Among all the drugs of a group of luteinizing hormone-releasing hormone agonists, leuprorelin acetate showed the best result in suppressing testosterone and PSA levels in urologic oncology practice. A clinical trial was done using different hormone treatment regimens, including orchiectomy, and different leuproprelin acetate therapy regimens. The drug was shown to be effective as compared to other hormone therapy options.

show abstract

“…Нюшко и соавт. сообщают о 28,6 % частоте полных ПСА-ответов, снижении уровня ПСА на 50 % и более у 71,4 % больных [13].…”

Section: Introductionunclassified

Salvage lymph node dissection in nodal oligorecurrent prostate cancer: literature review and our experience

Shirokorad,

Izmailov,

Lupashko

2024

Onkourologiâ

View full text Add to dashboard Cite

Background. Despite improved surgical techniques in treatment of prostate cancer, biochemical recurrence after surgery (increase in prostate-specific antigen level (PSA) by 0.2 mg/mL or higher in 2 consecutive measurements) develops in 20–40 % of patients depending on disease stage and tumor aggressiveness. To diagnose the source of biochemical recurrence, patients undergo positron emission tomography/computed tomography (PET/CT) with 18F- or 68Ga-labeled prostate-specific membrane antigen (PSMA). Both tracers showed comparable results in phase III trials with positive prognostic values between 84 and 92 % at PSA level ≥1 ng/mL. A number of articles has been published demonstrating the effectiveness of salvage lymph node dissection (SLND) after local treatment of carefully selected patients in the long-term. According to the results of these publications, drug therapy in patients with oligometastatic progression can be delayed by years and potentially increse overall survival.Aim. To analyze the literature and our own experience of SLND in treatment of nodal oligorecurrent prostate cancer.Materials and methods. At the Clinic of the Moscow City Oncological Hospital No. 62 between 2012 and 2023 in the frame-work of the clinical protocol, 32 patients with nodal oligorecurrent prostate cancer underwent SLND after radical prostatectomy: 12.5 % (4 of 32) of patients through open access, 87.5 % (28 of 32) through laparoscopic access.Results. Two groups were identified: 1st group (n = 20) of patients without androgen deprivation therapy (ADT) and/or external beam radiotherapy after SLND; 2nd group (n = 12) of patients receiving immediate ADT and/or external beam radiotherapy after SLND.In the 1st group, an additional criterion of SLND effectiveness was introduced, namely, PSA response: complete, partial PSA response, or its absence. In patients with partial PSA response (n = 4), its depth was evaluated; it varied between 16 and 83 %. PSA response depth did not correlate with duration of response.Complete PSA response was achieved in 60 % (n = 12) of patients. Duration of response varied between 3 and 133 months without additional treatment.In the 1st group, median follow-up was 6 months and progression-free survival was 18 months; in the 2nd group, median follow-up was 31 months and median progression-free survival was 41.9 months (p = 0.84456).Conclusion. The standard of treatment for patients with metastatic hormone-sensitive prostate cancer is ADT in combination with 2nd generation antiandrogens. Improvement and availability of PET/CT with PSMA allowed to identify patients with nodal oligorecurrent prostate cancer in which SLND without ADT allows to achieve complete PSA response in 60 % of cases and delay ADT associated with a number of adverse events. SLND is characterized by low number of postoperative complications, short hospital stay.

show abstract

Гормональная Терапия С Использованием Агонистов И Антагонистов Лютеинизи- Рующего Гормона Релизинг Гормона У Больных Раком Предстательной Железы

Cited by 4 publications

References 0 publications

Outcomes of radical prostatectomy in treatment of locally advanced prostate cancer: clinical observations

Outcomes of radical prostatectomy in treatment of locally advanced prostate cancer: clinical observations

Experience with a luteinizing hormone-releasing hormone agonist in patients with prostate cancer

Salvage lymph node dissection in nodal oligorecurrent prostate cancer: literature review and our experience

Contact Info

Product

Resources

About